Instil Bio, Inc.
instilbio.comWhat Do They Do?
Identifies and advances therapeutic opportunities, and seeks to acquire or in-license candidates for diseases with significant unmet medical need.
10-K for FY2025, filed Mar 27, 2026We are a biotechnology company focused on identifying and advancing innovative therapeutic opportunities.View ↗
We are actively seeking to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet…View ↗
Our strategy is to pursue potential acquisitions or in-licensing of therapeutic candidates.View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$4.3MView ↗
- ▼ −80% (Loss)
- vs −$21.4M in Q2 FY2025
-
Apr 3, 2026
Replaced Deloitte with RSM as independent auditor
The audit committee appointed RSM for fiscal 2026 and dismissed Deloitte; the company reported no disagreements with Deloitte.
Sources
8-K, filed Apr 3, 2026
On April 1, 2026, the Audit Committee of the Board of Directors of Instil Bio, Inc. (the “Company”) approved the appointment of RSM US LLP…View ↗
From cell therapies to broader candidates
The older report centered on developing genetically engineered TIL cell therapies for cancer through its CoStAR platform. The latest report describes seeking therapeutic candidates to in-license or acquire and develop, after discontinuing its former lead candidate.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 27, 2026In January 2026 we announced our wholly owned subsidiary, Axion Bio, Inc., or Axion Bio, was discontinuing development of our former lead…View ↗
We are actively seeking to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet…View ↗
Our strategy is to pursue potential acquisitions or in-licensing of therapeutic candidates.View ↗
Loading...
